Journal of Diabetes Research

Clinical Study

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

Table 3

Effect of bromocriptine-QR versus placebo on odds of losing glycemic control (HbA1C going above 7.0) and odds of requiring intensification of concomitant diabetes treatment regimen to maintain HbA1C ≤7.0.


	ITT: last observation carried forward (LOCF) analysis			Week 52 completer analysis

Effect of B-QR versus placebo on odds of losing good glycemic control (HbA1c exceeding 7.0) at study completion

Study Group	% subjects with HbA1c exceeding 7.0		Odds Ratio^a (CI), value	% Subjects with HbA1c exceeding 7.0		Odds Ratio^a (CI), value
	Placebo	B-QR		Placebo	B-QR

All subjects^b (baseline HbA1C ≤7.0)	24.7	15.2	0.505 (0.390, 0.653),	28.5	21.1	0.632 (0.471, 0.849),
	B-QR versus P Δ = −38.5%		B-QR versus P Δ = −26.0%

Subset of all subjects with no change in concomitant diabetes regimen during the study period^c	22.1	13.2	0.469 (0.341, 0.644),	25.6	17.7	0.558 (0.389, 0.800),
	B-QR versus P Δ = −40.3%		B-QR versus P Δ = −30.9%

Effect of B-QR versus placebo on odds of requiring intensification of concomitant diabetes treatment regimen to maintain HbA1C ≤7.0

Study Group	% Subjects intensifying regimen		Odds Ratio (CI), value	% Subjects intensifying regimen		Odds Ratio (CI), value
	Placebo	B-QR		Placebo	B-QR

Subset of all subjects that stayed in good glycemic control (HbA1c ≤ 7) during the study period^d	15.6	6.6	0.365 (0.256, 0.521),	17.9	9.5	0.463 (0.310, 0.690),
	B-QR versus P Δ = −57.7%		B-QR versus P Δ = −46.9%

Abbreviations: B-QR: bromocriptine-QR; P: placebo; CI: confidence interval.
^aAdjusted for baseline HbA1c.
^bCompleter: (B-QR: 750; placebo: 453); LOCF: (B-QR: 1219; placebo: 615).
^cCompleter: (B-QR: 586; placebo: 328); LOCF: (B-QR: 924; placebo: 434).
^dCompleter: (B-QR: 592; placebo: 324); LOCF: (B-QR: 1034; placebo: 463).